二黄扶正汤配合介入治疗原发性肝癌36例

目的：观察二黄扶正汤配合介入（肝动脉化疗栓塞治疗TACE）治疗原发性肝癌的临床疗效。方法：将66例患者随机分为治疗组36例和对照组30例，两组均接受TACE，治疗组在TACE的基础上加服二黄扶正汤。两组均治疗3个月后观察中医临床证候改善情况、2年生存率及并发症情况。结果临床证候改善率，治疗组为89％，对照组为50％，两组比较有显著性差异（P〈0．01）：2年生存率，治疗组为72％，对照组为37％，治疗组2年生存率明显高于对照组（P〈0．01）；两组出现腹痛、呕吐或体温超过38℃的并发症情况，治疗组较对照组明显减少，两组比较差异有显著性（P〈0．05）。结论：原发性肝癌在TACE的基础上加服二黄扶正汤可明显改善患者的临床证候、减少并发症及提高患者2年生存率。

Clinical effect of the Erhuang Fuzheng decoction combined with TACE on treating 36 cases of primary hepatic carcinoma

Objective： To investigate the clinical effect of Erhuang Fuzheng decoction combined with TACE on treating primary hepatic carcinoma. Methods： 66 patients were randomly divided into two groups, 36 in the treated group and 30 in the control group. Both groups were given TACE, while the treated group was given Erhuang Fuzheng decoction more. Results： The total effective rates in the treated group and the control group were 89% and 50% respectively, with significant differences （P〈0.01）. The 2 year survival rates in the treated group and the control group were 72% and 37% respectively, with significant differences （P〈0.01）. The complications in the treated group was much lower than those in the control group （P〈0.05）. Conclusion： Erhuang Fuzheng decoction combined with TACE was simaificantlv effective on treatin primary hepatic carcinoma.